<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053425</url>
  </required_header>
  <id_info>
    <org_study_id>CSBCL2</org_study_id>
    <secondary_id>ChiCTR2100045330</secondary_id>
    <nct_id>NCT05053425</nct_id>
  </id_info>
  <brief_title>Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML</brief_title>
  <official_title>Clinical Study of Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LanZhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective study, 30 newly untreated elderly patients with acute myeloid&#xD;
      leukemia(AML) who were not suitable for standard chemotherapy were enrolled to observe the&#xD;
      efficacy and side effects of venetoclax (VEN) combined with azacytidine (AZA) and&#xD;
      chemotherapy in newly treated elderly patients with AML. Overall survival (OS), complete&#xD;
      remission rate/complete remission with incomplete recovery of blood cell count (CR/ CRi) were&#xD;
      used as the primary endpoints, and time to response (TTR), duration of response (DOR),&#xD;
      mortality, and recurrence rate were used as secondary endpoints,and the incidence of adverse&#xD;
      events were evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction therapy: venetoclax d1 100mg, d2 200mg, d3-28 400mg, po; azacytidine 75mg/m2, d1-7,&#xD;
      sc. Consolidation therapy: Regimen A or B was chosen according to the wishes of the patients.&#xD;
      In addition, venetoclax was used for 14 days for positive minimal residual disease(MRD) and 7&#xD;
      days for MRD negative.&#xD;
&#xD;
      regimen A: the first two cycles: venetoclax 400mg, d1-7/14, po; cladribine 5mg/m2, d1-3,&#xD;
      ivgtt; cytarabine 10mg/m2, q12h, d1-10, sc; the last two cycles: venetoclax 400mg, d1-7/14,&#xD;
      po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; regimen B: the first two cycles: venetoclax 400mg,&#xD;
      d1-7/14, po; cytarabine 100mg/m2, d1-5/7, ivgtt; idarubicin 8mg/m2, d1-2/3, ivgtt; the last&#xD;
      two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; If the&#xD;
      patient's ECOG performance status ≥2, the reduction of regimen IA(cytarabine+idarubicin)was&#xD;
      5+2. Maintenance therapy: azacytidine 75mg/m2, d1-7, sc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 10, 2021</start_date>
  <completion_date type="Anticipated">March 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 16 months.</time_frame>
    <description>Overall survival will be defined as the number of days from the date of first dose to the date of death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CR/CRi</measure>
    <time_frame>up to 16 months.</time_frame>
    <description>To assess the percentage of patients achieving CR/CRi according to the International Working Group criteria for AML.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>up to 16 months.</time_frame>
    <description>To assess the percentage of patients achieving CR/CRi or partial remission (PR) according to the International Working Group criteria for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 16 months.</time_frame>
    <description>Duration of response will be defined as the number of days from the date of first response per the IWG criteria for AML to the earliest recurrence or progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 16 months.</time_frame>
    <description>The proportion of patients from enrollment to death was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>up to 16 months.</time_frame>
    <description>Record the proportion of patients with recurrence in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Adverse events were assessed weekly during the first and second cycles, and every two cycles thereafter (each cycle is 28 days), up to 16 months.</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Venetoclax group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy: venetoclax d1 100mg, d2 200mg, d3-28 400mg, po; azacytidine 75mg/m2, d1-7, sc.&#xD;
Consolidation therapy: Regimen A or B was chosen according to the wishes of the patients. In addition, venetoclax was used for 14 days for positive minimal residual disease(MRD) and 7 days for MRD negative.&#xD;
regimen A: the first two cycles: venetoclax 400mg, d1-7/14, po; cladribine 5mg/m2, d1-3, ivgtt; cytarabine 10mg/m2, q12h, d1-10, sc; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; regimen B: the first two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 100mg/m2, d1-5/7, ivgtt; idarubicin 8mg/m2, d1-2/3, ivgtt; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; If the patient's ECOG performance status ≥2,the reduction of regimen IA(cytarabine+idarubicin)was 5+2.&#xD;
Maintenance therapy: azacytidine 75mg/m2, d1-7, sc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>given po.</description>
    <arm_group_label>Venetoclax group</arm_group_label>
    <other_name>ABT-199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>given sc.</description>
    <arm_group_label>Venetoclax group</arm_group_label>
    <other_name>5-Azacytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>given ivgtt.</description>
    <arm_group_label>Venetoclax group</arm_group_label>
    <other_name>2-CdA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>given sc or ivgtt.</description>
    <arm_group_label>Venetoclax group</arm_group_label>
    <other_name>Ara-c</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>given ivgtt.</description>
    <arm_group_label>Venetoclax group</arm_group_label>
    <other_name>Idamycin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The elderly patients(≥ 60) with AML diagnosed according to WHO criteria;&#xD;
&#xD;
          2. Participants are ineligible for induction regimen;&#xD;
&#xD;
          3. The Eastern Cooperative Oncology Group (ECOG) performance status is 0-3;&#xD;
&#xD;
          4. The patients and their families agree and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment for AML (including hypomethylating agents and other chemotherapy&#xD;
             drugs);&#xD;
&#xD;
          2. Infiltration of the central nervous system;&#xD;
&#xD;
          3. Drugs use history affecting CYP3A within 7 days before enrollment;&#xD;
&#xD;
          4. participants considered by the investigator to be unsuitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Long Zhao, M.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Lanzhou University,Lanzhou,Gansu,China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Long Zhao, M.M.</last_name>
    <phone>+18919128021</phone>
    <email>zhaodragon@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Long Zhao</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Long Zhao</last_name>
      <phone>+18919128021</phone>
      <email>zhaodragon@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiushan Li</last_name>
      <phone>+8613893690080</phone>
      <email>ldyylwh@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LanZhou University</investigator_affiliation>
    <investigator_full_name>Long Zhao</investigator_full_name>
    <investigator_title>Doctor-in-charge, Master of Medicine</investigator_title>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Bcl-2 Inhibitors</keyword>
  <keyword>Azacytidine</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

